157 related articles for article (PubMed ID: 30178893)
1. Cervical cancer prevention: An Italian scenario between organised screening and human papillomaviruses vaccination.
Cappelli MG; Fortunato F; Tafuri S; Boccalini S; Bonanni P; Prato R; Martinelli D
Eur J Cancer Care (Engl); 2018 Sep; 27(5):e12905. PubMed ID: 30178893
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and cost of cervical cancer care and prevention in Apulia (Italy), 2007/2016.
Bianchi FP; Gallone MS; Fortunato F; Boccalini S; Martinelli D; Prato R; Tafuri S
Ann Ig; 2018; 30(6):490-501. PubMed ID: 30614498
[TBL] [Abstract][Full Text] [Related]
3. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
[TBL] [Abstract][Full Text] [Related]
4. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
6. Impact of HPV vaccination: health gains in the Italian female population.
Marcellusi A
Popul Health Metr; 2017 Sep; 15(1):36. PubMed ID: 28962572
[TBL] [Abstract][Full Text] [Related]
7. [Integrating cervical cancer screening and HPV vaccination: a pilot experience in the Apulia region of Italy].
Fortunato F; Cappelli MG; Prato R; Martinelli D;
Ig Sanita Pubbl; 2018; 74(3):265-277. PubMed ID: 30235467
[TBL] [Abstract][Full Text] [Related]
8. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
9. What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.
Lynge E; Antilla A; Arbyn M; Segnan N; Ronco G
Eur J Cancer; 2009 Oct; 45(15):2714-21. PubMed ID: 19695870
[TBL] [Abstract][Full Text] [Related]
10. Cervical cancer elimination in Italy: Current scenario and future endeavors for a value based prevention.
Calabrò GE; Riccardi MT; D'Ambrosio F; Castagna C; Sapienza M; Millevolte R; Pellacchia A; Ricciardi R; de Vincenzo RP; de Waure C
Front Public Health; 2022; 10():1010237. PubMed ID: 36530690
[TBL] [Abstract][Full Text] [Related]
11. Prevention of Cervical Cancer in Low-Resource African Settings.
Mulongo M; Chibwesha CJ
Obstet Gynecol Clin North Am; 2022 Dec; 49(4):771-781. PubMed ID: 36328679
[TBL] [Abstract][Full Text] [Related]
12. High-risk human papillomavirus genotypes in cervical lesions and vaccination challenges in China.
Xu QX; Zhang ZY
Asian Pac J Cancer Prev; 2015; 16(6):2193-7. PubMed ID: 25824736
[TBL] [Abstract][Full Text] [Related]
13. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.
Cameron RL; Kavanagh K; Cameron Watt D; Robertson C; Cuschieri K; Ahmed S; Pollock KG
J Epidemiol Community Health; 2017 Oct; 71(10):954-960. PubMed ID: 28756395
[TBL] [Abstract][Full Text] [Related]
14. Performance measures for Australian laboratories reporting cervical cytology 2009-2017: the impact of the national HPV vaccination program.
Ross J; Greaves J; Saville M; Earls P; Pagliuso J
Pathology; 2020 Aug; 52(5):522-528. PubMed ID: 32620288
[TBL] [Abstract][Full Text] [Related]
15. Age-specific HPV prevalence among 116,052 women in Australia's renewed cervical screening program: A new tool for monitoring vaccine impact.
Brotherton JM; Hawkes D; Sultana F; Malloy MJ; Machalek DA; Smith MA; Garland SM; Saville M
Vaccine; 2019 Jan; 37(3):412-416. PubMed ID: 30551987
[TBL] [Abstract][Full Text] [Related]
16. HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.
Palmer TJ; McFadden M; Pollock KG; Kavanagh K; Cuschieri K; Cruickshank M; Cotton S; Nicoll S; Robertson C
Br J Cancer; 2016 Mar; 114(5):582-9. PubMed ID: 26931370
[TBL] [Abstract][Full Text] [Related]
17. Cervical cancer control in the era of HPV vaccination and novel biomarkers.
Wentzensen N; Klug SJ
Pathobiology; 2009; 76(2):82-9. PubMed ID: 19367128
[TBL] [Abstract][Full Text] [Related]
18. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
El-Zein M; Richardson L; Franco EL
J Clin Virol; 2016 Mar; 76 Suppl 1(Suppl 1):S62-S68. PubMed ID: 26631958
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
20. A Retrospective Cohort Study of Young Women Spontaneously Choosing to Be Vaccinated against HPV: Outcomes from Their First Cervical Cancer Screening Test.
Del Mistro A; Battagello J; Weis L; Bressan V; Selle V; Ramigni M; Dal Zotto A; Maggiolo A; Gori S; Frayle H; Zappa M; Zorzi M; The Consensus Study Veneto Working Group
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
